BofA cuts Dentsply Sirona stock price target on guidance reset

BofA Securities cut its Dentsply Sirona price target to $14 from $17 while maintaining a Buy rating, citing a less encouraging Q3 update and a reset 2026 EPS midpoint of $1.10 excluding tariff refunds and inventory-elimination benefits. Recent Q3 2026 results missed estimates: adjusted EPS was $0.29 versus $0.3125 expected, and revenue was $836 million versus $862.76 million; the company also reduced its full-year outlook. BofA cited pockets of U.S. growth but said stabilization in connected technology, orthodontic and implant solutions remains ahead.

Analysis

The key underwriting question is whether “trough earnings” is real or merely a higher multiple applied to estimates that can still fall. Excluding tariff refunds and inventory-elimination benefits makes the $1.10 2026 EPS midpoint a cleaner reference, but it does not establish that the core profit base has stabilized. Weakness in Essential Dental Solutions would matter disproportionately because it could overwhelm early improvement in endodontics or implant offerings. Continued softness in connected technology, orthodontics, and implants also risks giving competitors such as Envista, Align Technology, and Straumann more time to capture customers; product-development spending and clinical education are not evidence of conversion until bookings and revenue show it.

Near term, the earnings miss and reset keep estimate revisions and confidence fragile; an analyst target or third-party fair value is not a catalyst. Over the next 1–3 months, track segment growth, organic revenue, margins, and guidance revisions—especially Essential Dental Solutions and evidence that customer conversions persist. Over 6–18 months, successful product adoption could support a recovery, but execution and competitive substitution are the central risks. The contrarian opportunity is that a depressed share price may already discount further disappointment; it is not compelling if the apparent earnings trough proves premature.

Key Decisions for Investors

• Do not buy solely on the gap between the share price and analyst/fair-value estimates. Treat XRAY as a watchlist turnaround until reported segment results confirm stabilization.
• For a tactical long, wait for evidence in the next quarterly report of improving Essential Dental Solutions trends and sustained connected-technology or orthodontic/implant stabilization, without another guidance cut. The setup is falsified by renewed deterioration in the profit engine or further downward EPS revisions.
• Existing holders should size against downside to a lower earnings base, not assume the stated 2027 multiple protects the stock. Monitor organic growth, segment margins, and whether reported improvement depends on temporary tariff or inventory benefits.
• Relative-value idea for further diligence, not an automatic pair: compare XRAY with Envista, Align Technology, and Straumann on customer wins and segment growth. Consider a relative short only if XRAY loses share while peers demonstrate durable growth; verify comparable exposures and valuation first.